LEXINGTON, Mass. / Feb 25, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York.
Panel Discussion Details:
Speaker: Robin Taylor, Ph.D., Chief Commercial Officer
Topic: “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”’
Date: 02/28/2025
Time: 1:00-2:00 p.m. ET
Location: New York City, NY
This event is for in-person participants only. Contact B. Riley for information on attending the conference.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
| Last Trade: | US$4.18 |
| Daily Change: | -0.07 -1.65 |
| Daily Volume: | 316,250 |
| Market Cap: | US$133.170M |
August 19, 2025 August 11, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
